Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 16 results.
User Information
Export Records
  1. 1.   IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma
  2. Bolomsky, Arnold; Ceribelli, Michele; Scheich, Sebastian; Rinaldi, Kristina; Huang, Da Wei; Chakraborty, Papiya; Pham, Lisette; Wright, George W; Hsiao, Tony; Morris, Vivian; Choi, Jaewoo; Phelan, James D; Holewinski,Ronald; Andresson,Thorkell; Wisniewski, Jan; Riley, Deanna; Pittaluga, Stefania; Hill, Elizabeth; Thomas, Craig J; Muppidi, Jagan; Young, Ryan M
  3. Cancer Cell. 2024, Jul 8; 42(7): 1185-1201.
  1. 2.   Low Spike Antibody Levels and Impaired BA.4/5 Neutralization in Patients with Multiple Myeloma or Waldenstrom's Macroglobulinemia after BNT162b2 Booster Vaccination
  2. Rosati, Margherita; Terpos, Evangelos; Bear,Jenifer; Burns,Robert; Devasundaram,Santhi; Ntanasis-Stathopoulos, Ioannis; Gavriatopoulou, Maria; Kastritis, Efstathios; Dimopoulos, Meletios-Athanasios; Pavlakis, George N; Felber,Barbara
  3. Cancers. 2022, Nov 25; 14(23):
  1. 3.   Caspase polymorphisms and genetic susceptibility to multiple myeloma
  2. Hosgood, H. D.; Baris, D.; Zhang, Y.; Zhu, Y.; Zheng, T.; Yeager, M.; Welch, R.; Zahm, S.; Chanock, S.; Rothman, N.; Lan, Q.
  3. Hematological Oncology. 2008 26(3): 148-151.
  1. 4.   Thalidomide analogues as anticancer drugs
  2. Aragon-Ching, J. B.; Li, H. Q.; Gardner, E. R.; Figg, W. D.
  3. Recent Patents on Anti-Cancer Drug Discovery. 2007, Jun; 2(2): 167-174.
  1. 5.   Reversal of p53 epigenetic silencing in multiple myeloma permits apoptosis by a p53 activator
  2. Hurt, E. M.; Thomas, S. B.; Peng, B.; Farrar, W. L.
  3. Cancer Biology & Therapy. 2006, Sep; 5(9): 1154-1160.
  1. 6.   JS-K, a GST-activated nitric oxide generator, induces apoptosis and overcomes in vitro drug resistance in multiple myeloma cells
  2. Kiziltepe, T.; Ishitsuka, K.; Hideshima, T.; Raje, N.; Shiraishi, N.; Yasui, H.; Catley, L.; Chauhan, D.; Saavedra, J. E.; Keefer, L. K.; Shami, P. J.; Anderson, K. C.
  3. Blood. 2005, NOV 16; 106(11, Part 1): 456A, Abstract 1593-456A, Abstract 1593.
  1. 7.   Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation
  2. Hodge, D. R.; Peng, B.; Cherry, J. C.; Hurt, E. M.; Fox, S. D.; Kelley, J. A.; Munroe, D. J.; Farrar, W. L.
  3. Cancer Research. 2005, JUN 1; 65(11): 4673-4682.
  1. 8.   Epigenetic silencing of the human nucleotide excision repair gene, hHR23B, in interleukin-6-responsive multiple myeloma KAS-6/1 cells
  2. Pengt, B.; Hodge, D. R.; Thomas, S. B.; Cherry, J. M.; Munroe, D. J.; Pompeia, C.; Xiao, W. H.; Farrar, W. L.
  3. Journal of Biological Chemistry. 2005, FEB 11; 280(6): 4182-4187.
  1. 9.   Nuclear receptors as negative modulators of STAT3 in multiple myeloma
  2. Wang, L. H.; Yang, X. Y.; Zhang, X. H.; Farrar, W. L.
  3. Cell Cycle. 2005, FEB; 4(2): 242-245.
  1. 10.   Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma
  2. Neelapu, S. S.; Munshi, N. C.; Jagannath, S.; Watson, T. M.; Pennington, R.; Barlogie, B.; Kwak, L. W.
  3. Blood. 2004, NOV 16; 104(11, Part 1, Abstract 3340): 913A-913A.
  1. 11.   NF-kappa B activates IL-6 expression through cooperation with c-Jun and IL6-AP1 site, but is independent of its IL6-NF kappa B regulatory site in autocrine human multiple myeloma cells
  2. Xiao, W. H.; Hodge, D. R.; Wang, L. H.; Yang, X. Y.; Zhang, X. H.; Farrar, W. L.
  3. Cancer Biology & Therapy. 2004, OCT; 3(10): 1007-1017.
  1. 12.   Activating mutations in STAT3 and STAT5 differentially affect cellular proliferation and apoptotic resistance in multiple myeloma cells
  2. Hodge, D. R.; Xiao, W. H.; Wang, L. H.; Li, D. P.; Farrar, W. L.
  3. Cancer Biology & Therapy. 2004 3(2): 188-194.
  1. 13.   Microarray analysis of epigenetic silencing of gene expression in the KAS-6/1 multiple myeloma cell line
  2. Pompeia, C.; Hodge, D. R.; Plass, C.; Wu, Y. Z.; Marquez, V. E.; Kelley, J. A.; Farrar, W. L.
  3. Cancer Research. 2004 64(10): 3465-3473.
  1. 14.   Transcriptional inactivation of STAT3 by PPAR gamma suppresses IL-6-responsive multiple myeloma cells
  2. Wang, L. H.; Yang, X. Y.; Zhang, X. H.; Huang, J. Q.; Hou, J.; Li, J.; Xiong, H.; Mihalic, K.; Zhu, H. M.; Xiao, W. H.; Farrar, W. L.
  3. Immunity. 2004 20(2): 205-218.
  1. 15.   Therapeutic idiotype vaccines in B lymphoproliferative diseases
  2. Coscia, M.; Kwak, L. W.
  3. Expert Opinion on Biological Therapy. 2004 4(6): 959-963.
  1. 16.   Recent advances in multiple myeloma immunotherapy
  2. Ruffini, P. A.; Biragyn, A.; Kwak, L. W.
  3. Biomedicine and Pharmacotherapy. 2002 56(3): 129-132.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel